Ignite Creation Date:
2025-12-25 @ 2:41 AM
Ignite Modification Date:
2026-03-02 @ 6:08 PM
Study NCT ID:
NCT01261533
Status:
UNKNOWN
Last Update Posted:
2013-05-23
First Post:
2010-12-15
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment
Sponsor:
Organization:
Raw JSON
{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D012163', 'term': 'Retinal Detachment'}], 'ancestors': [{'id': 'D012164', 'term': 'Retinal Diseases'}, {'id': 'D005128', 'term': 'Eye Diseases'}]}}, 'protocolSection': {'designModule': {'phases': ['PHASE1'], 'studyType': 'INTERVENTIONAL', 'designInfo': {'allocation': 'NA', 'maskingInfo': {'masking': 'NONE'}, 'primaryPurpose': 'TREATMENT', 'interventionModel': 'SINGLE_GROUP'}, 'enrollmentInfo': {'type': 'ESTIMATED', 'count': 122}}, 'statusModule': {'overallStatus': 'UNKNOWN', 'lastKnownStatus': 'RECRUITING', 'startDateStruct': {'date': '2010-09'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2013-05', 'completionDateStruct': {'date': '2014-06', 'type': 'ESTIMATED'}, 'lastUpdateSubmitDate': '2013-05-22', 'studyFirstSubmitDate': '2010-12-15', 'studyFirstSubmitQcDate': '2010-12-15', 'lastUpdatePostDateStruct': {'date': '2013-05-23', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2010-12-16', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-12', 'type': 'ESTIMATED'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Complete retinal reattach rate at the 52 weeks after implantation of the FCVB', 'timeFrame': '52 weeks after implantation of the FCVB'}], 'secondaryOutcomes': [{'measure': 'Retinal reattach rate, Visual function，and Silicone oil change', 'timeFrame': 'Before surgery, 3days,1 week, 2 weeks, 4 weeks, 8 weeks, 12 weeks, 24 weeks, 36 weeks and 52 weeks after FCVB implantation surgery (If patients ask for the delay of removal of FCVB, the patients must received a review every three months)', 'description': 'visual acuity, intraocular pressure, axial length, ocular inflammatory response, the number of corneal endothelial, emulsification rate of silicone oil, migration of silicone oil droplets into the anterior, chamber, anterior chamber angle and ciliary body change, morphological changes of the ocular and FCVB.'}]}, 'oversightModule': {'oversightHasDmc': True}, 'conditionsModule': {'keywords': ['vitreous body substitute', 'foldable capsular vitreous body'], 'conditions': ['Retinal Detachment']}, 'referencesModule': {'references': [{'pmid': '17525767', 'type': 'BACKGROUND', 'citation': 'Gao Q, Mou S, Ge J, To CH, Hui Y, Liu A, Wang Z, Long C, Tan J. A new strategy to replace the natural vitreous by a novel capsular artificial vitreous body with pressure-control valve. Eye (Lond). 2008 Mar;22(3):461-8. doi: 10.1038/sj.eye.6702875. Epub 2007 May 25.'}, {'pmid': '19264881', 'type': 'BACKGROUND', 'citation': 'Gao Q, Chen X, Ge J, Liu Y, Jiang Z, Lin Z, Liu Y. Refractive shifts in four selected artificial vitreous substitutes based on Gullstrand-Emsley and Liou-Brennan schematic eyes. Invest Ophthalmol Vis Sci. 2009 Jul;50(7):3529-34. doi: 10.1167/iovs.08-2802. Epub 2009 Mar 5.'}, {'pmid': '20618225', 'type': 'BACKGROUND', 'citation': 'Liu Y, Jiang Z, Gao Q, Ge J, Chen J, Cao X, Shen Q, Ma P. Technical standards of a foldable capsular vitreous body in terms of mechanical, optical, and biocompatible properties. Artif Organs. 2010 Oct;34(10):836-45. doi: 10.1111/j.1525-1594.2010.01006.x.'}, {'pmid': '19834025', 'type': 'BACKGROUND', 'citation': 'Liu Y, Ke Q, Chen J, Wang Z, Xie Z, Jiang Z, Ge J, Gao Q. Sustained mechanical release of dexamethasone sodium phosphate from a foldable capsular vitreous body. Invest Ophthalmol Vis Sci. 2010 Mar;51(3):1636-42. doi: 10.1167/iovs.09-4134. Epub 2009 Oct 15.'}, {'pmid': '20811065', 'type': 'BACKGROUND', 'citation': 'Lin X, Ge J, Gao Q, Wang Z, Long C, He L, Liu Y, Jiang Z. Evaluation of the flexibility, efficacy, and safety of a foldable capsular vitreous body in the treatment of severe retinal detachment. Invest Ophthalmol Vis Sci. 2011 Jan 21;52(1):374-81. doi: 10.1167/iovs.10-5869.'}, {'pmid': '21423138', 'type': 'BACKGROUND', 'citation': 'Zhang R, Wang T, Xie C, Lin X, Jiang Z, Wang Z, Liu Y, Luo Y, Long C, He L, Wang P, Gao Q. Evaluation of supporting role of a foldable capsular vitreous body with magnetic resonance imaging in the treatment of severe retinal detachment in human eyes. Eye (Lond). 2011 Jun;25(6):794-802. doi: 10.1038/eye.2011.61. Epub 2011 Mar 18.'}, {'pmid': '21883770', 'type': 'BACKGROUND', 'citation': 'Wang P, Gao Q, Jiang Z, Lin J, Liu Y, Chen J, Zhou L, Li H, Yang Q, Wang T. Biocompatibility and retinal support of a foldable capsular vitreous body injected with saline or silicone oil implanted in rabbit eyes. Clin Exp Ophthalmol. 2012 Jan-Feb;40(1):e67-75. doi: 10.1111/j.1442-9071.2011.02664.x. Epub 2011 Oct 20.'}, {'pmid': '22105508', 'type': 'BACKGROUND', 'citation': 'Lin X, Wang Z, Jiang Z, Long C, Liu Y, Wang P, Jin C, Yi C, Gao Q. Preliminary efficacy and safety of a silicone oil-filled foldable capsular vitreous body in the treatment of severe retinal detachment. Retina. 2012 Apr;32(4):729-41. doi: 10.1097/IAE.0b013e31822b1f80.'}]}, 'descriptionModule': {'briefSummary': 'The purpose of this study is to determine the feasibility, primary safety and efficacy of foldable capsular vitreous body (FCVB) in the treatment of retinal detachment, based on the multi-center clinical trial.', 'detailedDescription': 'Previous clinical trial have demonstrated that foldable artificial vitreous body (FCVB),with balanced salt solution (BSS) filled in 11 patients during three-months observation,or silicone oil filled in 4 patients during a six-month observation respectively, can be transplanted into the vitreous body easily, and performances good safety and efficacy in the treatment of severe retinal detachment.\n\nCurrent multi-center clinical trial was to determine the feasibility, primary safety and efficacy of FCVB with silicone oil filled in the treatment of retinal detachment in 120 patients.'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'maximumAge': '65 Years', 'minimumAge': '18 Years', 'healthyVolunteers': False, 'eligibilityCriteria': "Inclusion Criteria:\n\n1. age range from 18 to 65, Refractive error less than ±3D\n2. Corrected visual acuity less than 0.05\n3. ocular axial length is 16 to 25mm\n4. severe retinal detachment that can not be treated by current artificial vitreous body:\n\n 1. Severe unilateral ocular perforating injuries, compounded retinal or choroidal detachments resulted from retinal rupture or retinal choroidal hemorrhage.\n 2. Severe unilateral ocular rupture injuries result in retina or choroid defect.\n 3. Giant posterior scleral rupture injuries that can not be repaired.\n 4. Silicone oil can't be taken out for a long time with incomplete reattachment.\n 5. Participants have undergone retinal detachment surgery and silicone oil tamponade twice or more, however, retina is re-detachment after silicone oil removal.\n5. Participants can understand the aim of this clinical trial and sign the informed consent form\n\nExclusion Criteria:\n\n1. Participants have a silica gel allergy or scar diathesis\n2. entophthalmia\n3. uveitis\n4. The contralateral eye suffered from intraocular surgery\n5. uncontrollable the other eye diseases\n6. Corrected visual acuity of contralateral eye less than 0.4\n7. Proliferative diabetic retinopathy\n8. the lens of target eye is transparent\n9. Serious heart, lung, liver and kidney dysfunction\n10. pregnancy, preparation for pregnancy during clinical trial and breast-feeding female\n11. drug abuse or alcoholism\n12. participated the other drug or medical devices clinical trial before screening of this trial\n13. Any research doctors consider that the condition of participants will hinder the clinical trial--Prone to mental stress, loss control of mood, depression etc.\n14. Patient adherence is so poor that study procedures can not be finished"}, 'identificationModule': {'nctId': 'NCT01261533', 'briefTitle': 'Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment', 'organization': {'class': 'INDUSTRY', 'fullName': 'GuangZhou WeiShiBo Biotechnology Co., ltd'}, 'officialTitle': 'The Multi-center Exploratory Clinical Trials for the Evaluation of Flexibility, Efficacy, and Safety of a Foldable Capsular Vitreous Body in the Treatment of Severe Retinal Detachment', 'orgStudyIdInfo': {'id': 'VISBOR-61165995002'}}, 'armsInterventionsModule': {'armGroups': [{'type': 'EXPERIMENTAL', 'label': 'FCVB team', 'description': 'the vitreous cavity is tamponaded with the foldable capsular vitreous body (FCVB)', 'interventionNames': ['Device: foldable capsular vitreous body(FCVB)']}], 'interventions': [{'name': 'foldable capsular vitreous body(FCVB)', 'type': 'DEVICE', 'otherNames': ['FCVB'], 'description': 'FCVB with silicone oil inside is tamponaded into the vitreous cavity', 'armGroupLabels': ['FCVB team']}]}, 'contactsLocationsModule': {'locations': [{'zip': '100032', 'city': 'Beijing', 'state': 'Beijing Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'role': 'CONTACT', 'phone': '010-65296114'}], 'facility': 'Peking Union Medical College Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '100730', 'city': 'Beijing', 'state': 'Beijing Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'role': 'CONTACT', 'phone': '010-11616669'}], 'facility': 'Beijing Tongren Hospital', 'geoPoint': {'lat': 39.9075, 'lon': 116.39723}}, {'zip': '400038', 'city': 'Chongqing', 'state': 'Chongqing Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'role': 'CONTACT', 'phone': '023-65318301'}], 'facility': 'Southwest Hospital', 'geoPoint': {'lat': 29.56026, 'lon': 106.55771}}, {'zip': '510000', 'city': 'Guangzhou', 'state': 'Guangdong', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'name': 'Xia Huang', 'role': 'CONTACT', 'email': 'gaoketizu@163.com', 'phone': '020-87330490'}], 'facility': 'Zhongshan Ophthalmic Center, Sun Yat-sen University', 'geoPoint': {'lat': 23.11667, 'lon': 113.25}}, {'zip': '150001', 'city': 'Harbin', 'state': 'Heilongjiang', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'role': 'CONTACT', 'phone': '0451-86662961'}], 'facility': 'The 2nd affiliated hospital of Harbin Medicinal University.', 'geoPoint': {'lat': 45.75, 'lon': 126.65}}, {'zip': '430060', 'city': 'Wuhan', 'state': 'Hubei', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'role': 'CONTACT', 'phone': '027-88041911'}], 'facility': 'Renmin Hospital of Wuhan University', 'geoPoint': {'lat': 30.58333, 'lon': 114.26667}}, {'zip': '200031', 'city': 'Shanghai', 'state': 'Shanghai Municipality', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'role': 'CONTACT', 'phone': '021-64377134'}], 'facility': 'Eye and ENT Hospital of FuDan University', 'geoPoint': {'lat': 31.22222, 'lon': 121.45806}}, {'zip': '710032', 'city': 'Xian', 'state': 'Shanxi', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'role': 'CONTACT', 'phone': '029-3375015'}], 'facility': 'XiJing Hospital'}, {'zip': '325027', 'city': 'Wenzhou', 'state': 'Zhejiang', 'status': 'RECRUITING', 'country': 'China', 'contacts': [{'role': 'CONTACT', 'phone': '0577-88068822'}], 'facility': 'The affiliated Eye Hospital of Wenzhou Medical College', 'geoPoint': {'lat': 27.99942, 'lon': 120.66682}}], 'centralContacts': [{'name': 'Lian Zhou', 'role': 'CONTACT', 'email': 'vesber_zl@163.com', 'phone': '020-61165995'}], 'overallOfficials': [{'name': 'Qianying Gao, MD,Ph.D', 'role': 'PRINCIPAL_INVESTIGATOR', 'affiliation': 'Zhongshan Ophthalmic Center, Sun Yat-sen University'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'GuangZhou WeiShiBo Biotechnology Co., ltd', 'class': 'INDUSTRY'}, 'collaborators': [{'name': 'Sun Yat-sen University', 'class': 'OTHER'}], 'responsibleParty': {'type': 'SPONSOR'}}}}